Perimeter Medical’s Pivotal Trial Results to be Presented at ASBrS 2025

An announcement from Perimeter Medical Imaging AI ( (TSE:PINK) ) is now available.

Perimeter Medical Imaging AI announced that its pivotal trial results for the B-Series OCT with ImgAssist AI 2.0 will be presented at the 2025 Annual Meeting of the American Society of Breast Surgeons. The trial showed a statistically significant reduction in residual cancer during surgery, supporting the company’s efforts to gain FDA approval for their next-generation imaging system. This development could enhance the adoption of their technology, providing surgeons with improved tools for breast cancer surgery.

More about Perimeter Medical Imaging AI

Perimeter Medical Imaging AI, Inc., based in Toronto, Canada, and Dallas, Texas, is a commercial-stage medical technology company focused on transforming cancer surgery through advanced imaging tools. Their FDA-cleared Perimeter S-Series OCT system offers real-time, cross-sectional visualization of excised tissues, while their investigational Perimeter B-Series OCT with ImgAssist AI is being evaluated for its potential to enhance breast-conserving surgeries.

YTD Price Performance: 20.0%

Average Trading Volume: 84,804

Technical Sentiment Consensus Rating: Buy

Current Market Cap: C$47.79M

For a thorough assessment of PINK stock, go to TipRanks’ Stock Analysis page.